You are here

FDA Grants Priority Review for Promacta for Treatment of Thrombocytopenia in Adults With Chronic HCV

A Priority Review designation is given to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists. Under the Prescription Drugs User Fee Act, the goal for completing a Priority Review is 6 months.

Eltrombopag, known as Promacta in the U.S. and as Revolade in Europe, is currently approved in 89 countries around the world for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia.

Promacta may cause hepatotoxicity. Other risks include bone marrow reticulin formation and a risk for bone marrow fibrosis, thrombotic/thromboembolic complications, hematologic malignancies, and cataracts.

For more information, visit the Ligand Web site.

Recent Headlines

One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds